SCHEMBL5699359

SCHEMBL5699359

CCCOC(C)(C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22223405 0.87
SCHEMBL27905263 0.85 HSD17B10 (0.38) HSD17B10
SCHEMBL27892682 0.85 HSD17B10 (0.38) HSD17B10
SCHEMBL10332121 0.85 MAPK1 (0.33)
SCHEMBL24052154 0.84
SCHEMBL27797242 0.79 HSD17B10 (0.31) HSD17B10
SCHEMBL12318095 0.78 MAPK1 (0.40)
SCHEMBL9497562 0.78 HSD17B10 (0.33) HSD17B10
SCHEMBL12317874 0.77 ALDH1A1 (0.36)
SCHEMBL5699322 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305283-B1 PREPARATION OF DI-T-ALKYL PEROXIDES AND T-ALKYL HYDROPEROXIDES FROM N-ALKYL T-ALKYL ETHERS CHEMTURA CORP (US) 2006-08-09 EP claimed
EP-1305283-A1 PREPARATION OF DI-T-ALKYL PEROXIDES AND T-ALKYL HYDROPEROXIDES FROM N-ALKYL T-ALKYL ETHERS Crompton Corporation (US) 2003-05-02 EP claimed
WO-2001042206-A1 PREPARATION OF DI-T-ALKYL PEROXIDES AND T-ALKYL HYDROPEROXIDES FROM N-ALKYL T-ALKYL ETHERS CROMPTON CORPORATION (US) 2001-06-14 WO claimed
US-6225510-B1 WHERE N-ALKYL T-ALKYL ETHER AND HYDROGEN PEROXIDE OR ORGANIC HYDROPEROXIDE ARE REACTED IN ACID CATALYZED SYSTEM, PERFORMED AS IN SITU SINGLE STEP CROMPTON CORPORATION 2001-05-01 US claimed
US-20230322754-A1 IRAK INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-10-12 US disclosed
CN-101872123-B Radioactive rays sensitive resin compound, distance piece or protection film for liquid crystal display and forming method thereof JSR CORP 2013-07-24 CN disclosed
CN-102731112-A Solvent or solvent composition for producing laminated ceramic component DAICEL FINECHEM LTD 2012-10-17 CN disclosed
WO-2012091154-A1 METHOD OF PRODUCING A HYDROLYZABLE SILICON-CONTAINING COMPOUND WASEDA UNIVERSITY (JP) 2012-07-05 WO disclosed
CN-102043339-A Positive radiation-sensitive resin composition, and interlayer insulating film and method for forming the same JSR CORP 2011-05-04 CN disclosed
CN-101872123-A Radiation sensitive resin composition, liquid crystal display are with partition or diaphragm and forming method thereof JSR CORP 2010-10-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322754-A1 IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD17B10 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.